However, we suggest that a check for CD20 antigen positivity nevertheless be performed to adapt subsequent therapies for patients with relapsed or refractory follicular lymphoma, especially when immunotherapy against tumor target CD20 is targeted. The gene discussed is MS4A1; the disease is neoplasm.